Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

ClinicalTrials.gov Identifier: NCT04578834

Novartis Reference Number: CLNP023A2301

Last Update: Nov 24, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of LNP023 at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

Condition 
IgA Nephropathy
Phase 
Phase 3
Overall status 
Recruiting
Start date 
Jan 25, 2021
Completion date 
Jan 14, 2025
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Drug
Placebo
Placebo to LNP023 200mg b.i.d
Drug
LNP023
LNP023 200mg b.i.d

Eligibility Criteria

Inclusion Criteria:

Male and female patients ≥ 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows:
For patients eGFR* ≥ 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required.
For patients with eGFR* 30 to <45ml/min/1.73m2, a qualifying biopsy performed within 2 years with < 50% tubulointerstitial fibrosis is required.
For patients with eGFR* 20 to <30ml/min/1.73m2, a qualifying biopsy performed at any time.

In all cases, if a historical biopsy is not available, one may be performed during screening. *eGFR calculated using the CKD-EPI formula (or modified MDRD formula according to specific ethnic groups and local practice guidelines)

Proteinuria due to primary diagnosis of IgA nephropathy as assessed at screening by UPCR ≥1 g/g (113 mg/mmol) sampled from FMV or 24h urine collection, as well as at the completion of the run-in period by UPCR ≥1 g/g (113 mg/mmol) calculated as the (geometric) mean of two 24h urine collections obtained within 14 days of each other at baseline.
Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
If not previously vaccinated, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated.
All patients must have been on supportive care including stable dose regimen of ACEi or ARB at either the locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgment) for approximately 90 days before first study drug administration. In addition, if patients are taking diuretics, other antihypertensive medication, or other background medication for IgAN, the doses should also be stabilized for approximately 90 days prior to the first dosing of study treatment.

Exclusion Criteria:

Any secondary IgAN as defined by the investigator; secondary IgAN can be associated with cirrhosis, celiac disease, Human Immunodeficiency Virus (HIV) infection, dermatitis herpetiformis, seronegative arthritis, small-cell carcinoma, lymphoma, disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease, familial mediterranean fever, etc.
Sitting office SBP >140 mmHg or DBP >90 mmHg at the randomization visit
Patients previously treated with immunosuppressive or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (>7.5 mg/d prednisone/prednisolone equivalent) within 90 days (or 180 days for rituximab) prior to first study drug administration
Prior use of LNP023 or prior enrollment in any other LNP023 clinical trial where study drug was taken, including matching placebo
History of recurrent invasive infections caused by encapsulated organisms, such as meningococcus and pneumococcus.
Active systemic bacterial, viral (including COVID-19) or fungal infection within 14 days prior to study drug administration.

Other protocol-defined inclusion/exclusion criteria may apply.

Study Locations

United States
Novartis Investigative Site
Recruiting
Huntsville, 35805
Alabama
United States
Novartis Investigative Site
Recruiting
Glendale, 85308
Arizona
United States
Novartis Investigative Site
Recruiting
Phoenix, 85016
Arizona
United States
Novartis Investigative Site
Recruiting
Fresno, 93720
California
United States
Novartis Investigative Site
Recruiting
Garden Grove, 92844
California
United States
Novartis Investigative Site
Recruiting
Salinas, 93901
California
United States
Novartis Investigative Site
Recruiting
San Diego, 92111
California
United States
Novartis Investigative Site
Recruiting
San Dimas, 91773
California
United States
Novartis Investigative Site
Recruiting
Aurora, 80045
Colorado
United States
Novartis Investigative Site
Recruiting
Denver, 80210
Colorado
United States
Novartis Investigative Site
Recruiting
Newark, 19713
Delaware
United States
Novartis Investigative Site
Recruiting
Gainesville, 32610
Florida
United States
Novartis Investigative Site
Recruiting
Hollywood, 33021
Florida
United States
Novartis Investigative Site
Recruiting
Jacksonville, 32224
Florida
United States
Novartis Investigative Site
Recruiting
Miami, 33155
Florida
United States
Novartis Investigative Site
Recruiting
Nampa, 83687
Idaho
United States
Novartis Investigative Site
Recruiting
Hinsdale, 60521
Illinois
United States
Novartis Investigative Site
Recruiting
Iowa City, 52242
Iowa
United States
Novartis Investigative Site
Recruiting
Baton Rouge, 80808
Louisiana
United States
Novartis Investigative Site
Recruiting
Metairie, 70006
Louisiana
United States
Novartis Investigative Site
Recruiting
Baltimore, 21287
Maryland
United States
Novartis Investigative Site
Recruiting
Boston, 02115
Massachusetts
United States
Novartis Investigative Site
Recruiting
Ann Arbor, 48109
Michigan
United States
Novartis Investigative Site
Recruiting
Rochester, 55905
Minnesota
United States
Novartis Investigative Site
Recruiting
Kansas City, 64111
Missouri
United States
Novartis Investigative Site
Recruiting
Saint Louis, 63141
Missouri
United States
Novartis Investigative Site
Recruiting
Las Vegas, 89106
Nevada
United States
Novartis Investigative Site
Recruiting
Jersey City, 07305
New Jersey
United States
Novartis Investigative Site
Recruiting
Albuquerque, 87131
New Mexico
United States
Novartis Investigative Site
Recruiting
Albany, 12208
New York
United States
Novartis Investigative Site
Recruiting
New York, 10016
New York
United States
Novartis Investigative Site
Recruiting
New York, 10032
New York
United States
Novartis Investigative Site
Recruiting
Cincinnati, 45267
Ohio
United States
Novartis Investigative Site
Recruiting
Cleveland, 44195
Ohio
United States
Novartis Investigative Site
Recruiting
Philadelphia, 19107
Pennsylvania
United States
Novartis Investigative Site
Recruiting
Dallas, 75230
Texas
United States
Novartis Investigative Site
Recruiting
Dallas, 75235
Texas
United States
Novartis Investigative Site
Recruiting
El Paso, 79935
Texas
United States
Novartis Investigative Site
Recruiting
Houston, 77054
Texas
United States
Novartis Investigative Site
Recruiting
San Antonio, 78229 3900
Texas
United States
Novartis Investigative Site
Recruiting
Temple, 76502
Texas
United States
Novartis Investigative Site
Recruiting
Salt Lake City, 84115
Utah
United States
Novartis Investigative Site
Recruiting
Seattle, 98104
Washington
United States
Novartis Investigative Site
Recruiting
Marshfield, 54449
Wisconsin
United States
Argentina
Novartis Investigative Site
Recruiting
Caba, C1181ACH
Buenos Aires
Argentina
Novartis Investigative Site
Recruiting
Ciudad Autonoma de Buenos Aire, 1426
-
Argentina
Novartis Investigative Site
Recruiting
Cordoba, X5016JDA
-
Argentina
Novartis Investigative Site
Recruiting
Cordoba, X5016KEH
-
Argentina
Novartis Investigative Site
Recruiting
Santa Fe, S3000EPV
-
Argentina
Australia
Novartis Investigative Site
Recruiting
Westmead, 2145
New South Wales
Australia
Novartis Investigative Site
Recruiting
Woolloongabba, 4102
Queensland
Australia
Novartis Investigative Site
Recruiting
Adelaide, 5000
South Australia
Australia
Novartis Investigative Site
Recruiting
Parkville, 3065
Victoria
Australia
Belgium
Novartis Investigative Site
Recruiting
Edegem, 2650
Antwerpen
Belgium
Novartis Investigative Site
Recruiting
Leuven, 3000
-
Belgium
Novartis Investigative Site
Recruiting
Roeselare, 8800
-
Belgium
Brazil
Novartis Investigative Site
Recruiting
Belo Horizonte, 30150-221
MG
Brazil
Novartis Investigative Site
Recruiting
Curitiba, 80440-020
PR
Brazil
Novartis Investigative Site
Recruiting
Porto Alegre, 90020-090
RS
Brazil
Novartis Investigative Site
Recruiting
Sao Paulo, 05403 000
SP
Brazil
Novartis Investigative Site
Recruiting
São Paulo, 04038-002
SP
Brazil
Novartis Investigative Site
Recruiting
Sao Jose do Rio Preto, 15090 000
-
Brazil
Canada
Novartis Investigative Site
Recruiting
Oshawa, L1G 2B9
Ontario
Canada
China
Novartis Investigative Site
Recruiting
Beijing, 102218
Beijing
China
Novartis Investigative Site
Recruiting
Guangzhou, 510080
Guangdong
China
Novartis Investigative Site
Recruiting
Shenzhen, 518000
Guangdong
China
Novartis Investigative Site
Recruiting
Changsha, 410011
Hunan
China
Novartis Investigative Site
Recruiting
Changchun, 130041
Jilin
China
Novartis Investigative Site
Recruiting
Yinchuan, 100039
Ningxia
China
Novartis Investigative Site
Recruiting
Taiyuan, 030001
Shanxi
China
Novartis Investigative Site
Recruiting
Xi'an, 710004
Shanxi
China
Novartis Investigative Site
Recruiting
Hangzhou, 310003
Zhejiang
China
Novartis Investigative Site
Recruiting
Wenzhou, 325000
Zhejiang
China
Novartis Investigative Site
Recruiting
Beijing, 100029
-
China
Novartis Investigative Site
Recruiting
Beijing, 100034
-
China
Novartis Investigative Site
Recruiting
Guang Zhou, 510080
-
China
Novartis Investigative Site
Recruiting
Ningbo, 315010
-
China
Novartis Investigative Site
Recruiting
Qingdao, 266000
-
China
Novartis Investigative Site
Recruiting
Shanghai, 200025
-
China
Novartis Investigative Site
Recruiting
Shanghai, 200040
-
China
Novartis Investigative Site
Recruiting
Shanxi Province,
-
China
Novartis Investigative Site
Recruiting
Shenzhen, 518036
-
China
Novartis Investigative Site
Recruiting
Zhejiang,
-
China
Colombia
Novartis Investigative Site
Recruiting
Medellin, 050001
Antioquia
Colombia
Novartis Investigative Site
Recruiting
Barranquilla,
-
Colombia
Czech Republic
Novartis Investigative Site
Recruiting
Hradec Kralove, 500 05
CZE
Czech Republic
Novartis Investigative Site
Recruiting
Praha, 12808
-
Czech Republic
Denmark
Novartis Investigative Site
Recruiting
Aalborg, 9000
-
Denmark
Novartis Investigative Site
Recruiting
Arhus N, DK-8200
-
Denmark
Novartis Investigative Site
Recruiting
Copenhagen, DK-2100
-
Denmark
Novartis Investigative Site
Recruiting
Odense, 5000
-
Denmark
Finland
Novartis Investigative Site
Recruiting
HUS, 00029
-
Finland
Novartis Investigative Site
Recruiting
Turku, 20520
-
Finland
France
Novartis Investigative Site
Recruiting
Marseille Cédex 5, 13385
-
France
Novartis Investigative Site
Recruiting
Montpellier, 34295
-
France
Novartis Investigative Site
Recruiting
Paris, 75015
-
France
Germany
Novartis Investigative Site
Recruiting
Aachen, 52074
-
Germany
Novartis Investigative Site
Recruiting
Berlin, 13353
-
Germany
Novartis Investigative Site
Recruiting
Dresden, 01307
-
Germany
Novartis Investigative Site
Recruiting
Essen, 45147
-
Germany
Novartis Investigative Site
Recruiting
Frankfurt, 60590
-
Germany
Novartis Investigative Site
Recruiting
Freiburg, 79106
-
Germany
Novartis Investigative Site
Recruiting
Gottingen, 37075
-
Germany
Novartis Investigative Site
Recruiting
Hannover, 30625
-
Germany
Novartis Investigative Site
Recruiting
Magdeburg, 39120
-
Germany
Novartis Investigative Site
Recruiting
Mainz, 55131
-
Germany
Novartis Investigative Site
Recruiting
Muenchen, 81377
-
Germany
Novartis Investigative Site
Recruiting
Stuttgart, 70376
-
Germany
Novartis Investigative Site
Recruiting
Tübingen, 72076
-
Germany
Novartis Investigative Site
Recruiting
Ulm, 89081
-
Germany
Hungary
Novartis Investigative Site
Recruiting
Debrecen, 4032
-
Hungary
Novartis Investigative Site
Recruiting
Pecs, 7623
-
Hungary
India
Novartis Investigative Site
Recruiting
New Delhi, 110 017
Delhi
India
Novartis Investigative Site
Recruiting
Bangalore, 560004
Karnataka
India
Novartis Investigative Site
Recruiting
DehraDun, 248001
Uttarakhand
India
Novartis Investigative Site
Recruiting
New Delhi, 110029
-
India
Israel
Novartis Investigative Site
Recruiting
Ashkelon, 78278
-
Israel
Novartis Investigative Site
Recruiting
Jerusalem, 9112001
-
Israel
Novartis Investigative Site
Recruiting
Kfar Saba, 44281
-
Israel
Novartis Investigative Site
Recruiting
Petach Tikva, 4941492
-
Israel
Italy
Novartis Investigative Site
Recruiting
Ranica, 24020
BG
Italy
Novartis Investigative Site
Recruiting
Bologna, 40138
BO
Italy
Novartis Investigative Site
Recruiting
Napoli, 80100
-
Italy
Japan
Novartis Investigative Site
Recruiting
Kasugai, 486-8510
Aichi
Japan
Novartis Investigative Site
Recruiting
Toyoake city, 470 1192
Aichi
Japan
Novartis Investigative Site
Recruiting
Toyota, 471-8513
Aichi
Japan
Novartis Investigative Site
Recruiting
Chiba-city, 260-8712
Chiba
Japan
Novartis Investigative Site
Recruiting
Kitakyushu-city, 802-8555
Fukuoka
Japan
Novartis Investigative Site
Recruiting
Sapporo-city, 006-8555
Hokkaido
Japan
Novartis Investigative Site
Recruiting
Sapporo-city,
Hokkaido
Japan
Novartis Investigative Site
Recruiting
Kahoku-gun, 920-0293
Ishikawa
Japan
Novartis Investigative Site
Recruiting
Kawasaki, 213-8587
Kanagawa
Japan
Novartis Investigative Site
Recruiting
Yokohama-city, 236-0004
Kanagawa
Japan
Novartis Investigative Site
Recruiting
Yokohama, 224-8503
Kanagawa
Japan
Novartis Investigative Site
Recruiting
Sendai, 981-3205
Miyagi
Japan
Novartis Investigative Site
Recruiting
Matsumoto-city, 390-8621
Nagano
Japan
Novartis Investigative Site
Recruiting
Okayama-city, 700-8558
Okayama
Japan
Novartis Investigative Site
Recruiting
Tomigusuku, 901-0224
Okinawa
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 530-0012
Osaka
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 530-8480
Osaka
Japan
Novartis Investigative Site
Recruiting
Osaka-city, 558-8558
Osaka
Japan
Novartis Investigative Site
Recruiting
Omihachiman, 523-0082
Shiga
Japan
Novartis Investigative Site
Recruiting
Bunkyo ku, 113-8431
Tokyo
Japan
Novartis Investigative Site
Recruiting
Kyoto, 605-0981
-
Japan
Novartis Investigative Site
Recruiting
Niigata, 951 8520
-
Japan
Novartis Investigative Site
Recruiting
Osaka, 534-0021
-
Japan
Novartis Investigative Site
Recruiting
Toyama, 930-8550
-
Japan
Korea, Republic of
Novartis Investigative Site
Recruiting
Cheongju si, 28644
Chungcheongbuk Do
Korea, Republic of
Novartis Investigative Site
Recruiting
Bundang Gu, 13620
Gyeonggi Do
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 03312
Korea
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 06591
Seocho Gu
Korea, Republic of
Novartis Investigative Site
Recruiting
Busan, 47392
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 02841
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 03080
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 03722
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 06973
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul, 134 727
-
Korea, Republic of
Novartis Investigative Site
Recruiting
Taegu, 41944
-
Korea, Republic of
Malaysia
Novartis Investigative Site
Recruiting
Kuala Lumpur, 50589
-
Malaysia
Novartis Investigative Site
Recruiting
Kuala Lumpur, 59100
-
Malaysia
Mexico
Novartis Investigative Site
Recruiting
Mexicali, 21200
Baja California Norte
Mexico
Novartis Investigative Site
Recruiting
Culiacan Sinaloa, 80230
-
Mexico
Novartis Investigative Site
Recruiting
Queretaro, 76000
-
Mexico
Netherlands
Novartis Investigative Site
Recruiting
Groningen, 9713 GZ
-
Netherlands
Norway
Novartis Investigative Site
Recruiting
Lorenskog, 1478
Oslo
Norway
Novartis Investigative Site
Recruiting
Bergen, 5021
-
Norway
Singapore
Novartis Investigative Site
Recruiting
Singapore, 119228
-
Singapore
Novartis Investigative Site
Recruiting
Singapore, 169608
-
Singapore
Slovakia
Novartis Investigative Site
Recruiting
Bratislava, 833 05
Slovak Republic
Slovakia
Novartis Investigative Site
Recruiting
Kosice, 04011
-
Slovakia
Slovenia
Novartis Investigative Site
Recruiting
Ljubljana, 1000
-
Slovenia
Spain
Novartis Investigative Site
Recruiting
Cordoba, 14004
Andalucia
Spain
Novartis Investigative Site
Recruiting
Barcelona, 08036
Catalunya
Spain
Novartis Investigative Site
Recruiting
Burela, 27880
Lugo
Spain
Novartis Investigative Site
Recruiting
Madrid, 28041
-
Spain
Sweden
Novartis Investigative Site
Recruiting
Danderyd, 182 88
-
Sweden
Novartis Investigative Site
Recruiting
Linkoping, 581 85
-
Sweden
Novartis Investigative Site
Recruiting
Stockholm, 141 86
-
Sweden
Taiwan
Novartis Investigative Site
Recruiting
Kaohsiung City, 83301
-
Taiwan
Novartis Investigative Site
Recruiting
New Taipei City, 23561
-
Taiwan
Novartis Investigative Site
Recruiting
New Taipei, 22060
-
Taiwan
Novartis Investigative Site
Recruiting
Taichung, 40447
-
Taiwan
Novartis Investigative Site
Recruiting
Taipei, 10048
-
Taiwan
Novartis Investigative Site
Recruiting
Taoyuan, 33305
-
Taiwan
Thailand
Novartis Investigative Site
Recruiting
Bangkok, 10330
-
Thailand
Novartis Investigative Site
Recruiting
Bangkok, 10400
-
Thailand
Novartis Investigative Site
Recruiting
Bangkok, 10700
-
Thailand
Turkey
Novartis Investigative Site
Recruiting
Istanbul, 34265
Sultangazi
Turkey
Novartis Investigative Site
Recruiting
Istanbul, 34098
TUR
Turkey
Novartis Investigative Site
Recruiting
Ankara, 06500
-
Turkey
Novartis Investigative Site
Recruiting
Istanbul, 34093
-
Turkey
Novartis Investigative Site
Recruiting
Istanbul, 34371
-
Turkey
Novartis Investigative Site
Recruiting
Kocaeli, 41380
-
Turkey
Novartis Investigative Site
Recruiting
Mersin, 33079
-
Turkey
Novartis Investigative Site
Recruiting
Talas / Kayseri, 38039
-
Turkey
United Kingdom
Novartis Investigative Site
Recruiting
Salford, M6 8HD
Manchester
United Kingdom
Novartis Investigative Site
Recruiting
Leicester, LE5 4PW
-
United Kingdom
Novartis Investigative Site
Recruiting
London, SE5 9RS
-
United Kingdom
Novartis Investigative Site
Recruiting
London, SW17 0QT
-
United Kingdom
Novartis Investigative Site
Recruiting
Newcastle Upon Tyne, NE7 7DN
-
United Kingdom
Vietnam
Novartis Investigative Site
Recruiting
Ho Chi Minh, 700000
VNM
Vietnam
Novartis Investigative Site
Recruiting
Ho Chi Minh, 700000
-
Vietnam

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]